Trial
NCT05622058
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Aileron Therapeutics, Inc.
Collaborators
—
Condition
Prevention of Chemotherapy-induced Myelosuppression
Intervention
ALRN-6924
Why stopped
The study has been terminated early given that the first four patients enrolled have experienced Grade 4 neutropenia and alopecia after cycle 1 and as such failed to meet the primary endpoint and the main secondary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-27